Drug Trial Radar · NCT05207865
Safety and Tolerability Study of Daily Dosing Rimegepant in Episodic Migraine Prevention
Last checked: Nov 20, 2026Latest source record: Sep 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
441
Actual
Start
Mar 15, 2022
Primary completion
Jul 2, 2024
Study completion Jul 2, 2024
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Jan 26, 2022
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to further evaluate the long-term safety and tolerability of daily dosing of rimegepant for the prevention of episodic migraine.
Conditions
- Migraine
- Episodic Migraine
- Phonophobia
- Photophobia
Interventions
RimegepantDrug
rimegepant ODT 75mg daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With On-Treatment Adverse Events (AEs) (Frequency >=5%) According to IntensityTime frame: From start of study treatment (Day 1) up to 7 days after the last dose of study treatment (Up to 25 weeks)
- Number of Participants With On-Treatment Serious Adverse Events (SAEs)Time frame: From start of study treatment (Day 1) up to 7 days after the last dose of study treatment (Up to 25 weeks)
- Number of Participants With AEs Leading to Study Drug DiscontinuationTime frame: From start of study treatment (Day 1) up to 7 days after the last dose of study treatment (Up to 25 weeks)
- Number of Participants With Grade 3 to 4 Laboratory Abnormalities On-Treatment Using Common Technical Criteria for Adverse Events- Division of Acquired Immune Deficiency Syndrome (CTCAE/DAIDS) Toxicity Grading ScaleTime frame: From start of study treatment (Day 1) up to 7 days after the last dose of study treatment (Up to 25 weeks)
- Number of Participants With Grade 3 to 4 Laboratory Abnormalities On-Treatment Using Food and Drug Administration (FDA) Toxicity Grading ScaleTime frame: From start of study treatment (Day 1) up to 7 days after the last dose of study treatment (Up to 25 weeks)
Locations
19 sites in 1 country. Site status is shown where the registry gives one.
Elite Clinical Studies, LLC
Phoenix, Arizona
Advanced Investigative Medicine, Inc.
Hawthorne, California
Velocity Clinical Research - North Hollywood
North Hollywood, California
Chase Medical Research, LLC
Waterbury, Connecticut
Phoenix Medical Research, LLC
Miami, Florida
The Headache Clinic
Alexandria, Louisiana
Boston Clinical Trials
Boston, Massachusetts
Michigan Head Pain & Neurological Institute
Ann Arbor, Michigan
CVS HealthHub - East Brunswick
East Brunswick, New Jersey
CVS HealthHub - Lawrenceville
Lawrenceville, New Jersey
CVS HealthHUB - Runnemede
Runnemede, New Jersey
SPRI Clinical Trials, LLC
Brooklyn, New York
Velocity Clinical Research
Cincinnati, Ohio
OK Clinical Research, LLC
Edmond, Oklahoma
Clinical Research Philadelphia, LLC
Philadelphia, Pennsylvania
WR-ClinSearch, LLC
Chattanooga, Tennessee
VIP Trails
San Antonio, Texas
VIP Trials
San Antonio, Texas
Tidewater Integrated Medical Research
Virginia Beach, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.